{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:14:53Z","timestamp":1791976493547,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,3,15]]},"DOI":"10.1086\/319375","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T17:32:28Z","timestamp":1027704748000},"page":"S39-S46","source":"Crossref","is-referenced-by-count":104,"title":["What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?"],"prefix":"10.1093","volume":"32","author":[{"given":"Jerome J.","family":"Schentag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Gilliland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Paladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2001,3,15]]},"reference":[{"key":"key\n\t\t\t\t20171014022933_R1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of \u03b2-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014022933_R2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/514620","article-title":"The pharmacodynamics of aminoglycosides","volume":"27","author":"Lacy","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014022933_R3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/infdis\/153.1.90","article-title":"Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics","volume":"153","author":"Gerber","year":"1986","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014022933_R4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose effect relations at several dosing intervals in murine pneumonitis and thigh infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014022933_R5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/106002809402800707","article-title":"Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime","volume":"28","author":"Goss","year":"1994","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171014022933_R7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/514621","article-title":"Pharmacodynamic interactions of antibiotics alone and in combination","volume":"27","author":"Schentag","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014022933_R8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/106002809102501003","article-title":"Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin","volume":"25","author":"Schentag","year":"1991","journal-title":"DICP"},{"issue":"Suppl A","key":"key\n\t\t\t\t20171014022933_R9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/43.suppl_1.55","article-title":"Antibiotic dosing issues in lower respiratory tract infections: population-derived area under inhibitory curve is predictive of efficacy","volume":"43","author":"Highet","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R10","article-title":"A randomized, parallel group comparison of the bacterial eradication pharmacokinetics and pharmacodynamics of ciprofloxacin, vs azithromy cin, vs clarithromycin in patients with chronic bronchitis","volume-title":"J Antimicrob Chemother","author":"Ballow","year":"2001"},{"key":"key\n\t\t\t\t20171014022933_R11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/514934","article-title":"Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Bronchitis Study Group","volume":"27","author":"Chodosh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014022933_R12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1128\/AAC.40.5.1148","article-title":"Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model","volume":"40","author":"Cappelletty","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R14","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1128\/AAC.42.11.2914","article-title":"In vitro selection of resistance to four \u03b2-lactams and azithromycin in Streptococcus pneumoniae","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"key\n\t\t\t\t20171014022933_R15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/38.suppl_A.71","article-title":"Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992\u201393 Western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group","volume":"38","author":"Goldstein","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl A","key":"key\n\t\t\t\t20171014022933_R17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/40.suppl_1.45","article-title":"Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis","volume":"40","author":"Forrest","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014022933_R19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.43.3.672","article-title":"Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection","volume":"43","author":"Lacy","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jac\/41.4.481","article-title":"Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus","volume":"41","author":"Schmitz","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014022933_R21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/43.suppl_2.1","article-title":"A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new \u201crespiratory quinolones\u201d","volume":"43","author":"Blondeau","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/40.6.797","article-title":"Concentration-dependent killing of antibioticresistant pneumococci by the methoxyquinolone moxifloxacin","volume":"40","author":"Klugman","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/42.6.803","article-title":"Moxifloxacin: a comparison with other antimicrobial agents of in vitro activity against Streptococcus pneumoniae","volume":"42","author":"Reinert","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/AAC.43.2.421","article-title":"Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and-susceptible Staphylococcus aureus strains","volume":"43","author":"Jones","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.43.2.302","article-title":"ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae","volume":"43","author":"Varon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R26","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/AAC.42.11.2956","article-title":"Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract","volume":"42","author":"Piddock","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1128\/AAC.43.7.1560","article-title":"Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection","volume":"43","author":"MacGowan","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/42.6.803","article-title":"Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae","volume":"42","author":"Reinert","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014022933_R29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/43.suppl_2.83","article-title":"Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man","volume":"43","author":"Stass","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014022933_R30","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1128\/AAC.42.8.2060","article-title":"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects","volume":"42","author":"Stass","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014022933_R31","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1128\/AAC.43.6.1508","article-title":"Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration","volume":"43","author":"Wise","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014022933_R32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/43.suppl_2.43","article-title":"Bactericidal properties of moxifloxacin and post-antibiotic effect","volume":"43","author":"Boswell","year":"1999","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/32\/Supplement_1\/S39\/20903799\/32-Supplement_1-S39.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T04:01:11Z","timestamp":1583294471000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/32\/Supplement_1\/S39\/297476\/What-Have-We-Learned-from-Pharmacokinetic-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,15]]},"references-count":32,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2001,3,15]]},"published-print":{"date-parts":[[2001,3,15]]}},"URL":"https:\/\/doi.org\/10.1086\/319375","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2001,3,15]]},"published":{"date-parts":[[2001,3,15]]}}}